BNAI stock doubles as Brand Engagement Network lands AI pharma deal, eyes recurring fees
Brand Engagement Network, Inc shares more than doubled on Monday after the company disclosed a project agreement to develop a custom AI engagement tool tied to an established prescription drug for a top-10 global pharmaceutical client. The company said it expects $250,000 in fourth-quarter development revenue and anticipates monthly license fees starting in the first quarter of 2026; the stock closed up 108.8% at $2.51. SEC+1
